RPL8

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, RPL8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPL8 data layer compared with 27 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher RPL8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL8 expression acts as an unfavorable survival marker.

SCLC and KICH are the cancer types where RPL8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SCLCDFSMedianII,III,IV0.1370.602.00818view →
KICHDFSMedianAll0.1020.848.00413view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPL8–SCLC (DFS)

Kaplan–Meier survival curve for RPL8 mutant vs wild-type samples in SCLC.

Open the SCLC breakdown →

Exploration